Detalles de la búsqueda
1.
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer
; 23(1): 6, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36597021
2.
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
Int J Clin Oncol
; 28(5): 654-663, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856908
3.
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Cancer Immunol Immunother
; 71(9): 2109-2116, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35037070
4.
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
BMC Cancer
; 22(1): 1148, 2022 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348317
5.
Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.
BMC Cancer
; 22(1): 775, 2022 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35840951
6.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Cancer Sci
; 112(1): 72-80, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084148
7.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 25(4): e679-e683, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297443
8.
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
BMC Cancer
; 20(1): 103, 2020 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32028909
9.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Cancer Sci
; 110(10): 3244-3254, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368625
10.
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
Cancer Sci
; 109(8): 2539-2548, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29900633
11.
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
BMC Cancer
; 18(1): 826, 2018 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30115035
12.
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Br J Cancer
; 117(10): 1450-1458, 2017 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28972961
13.
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.
Proc Natl Acad Sci U S A
; 111(33): 12234-9, 2014 Aug 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092296
14.
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Cancer Sci
; 107(3): 307-14, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26708016
15.
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC Cancer
; 16(1): 864, 2016 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27821131
16.
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation.
Proc Natl Acad Sci U S A
; 110(21): 8690-5, 2013 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23610442
17.
The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.
J Biol Chem
; 288(22): 15813-20, 2013 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-23615903
18.
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor ß2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Cancer Sci
; 105(6): 683-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24698130
19.
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Cancer
; 120(10): 1471-81, 2014 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24700479
20.
Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.
J Virol
; 87(1): 648-58, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23097450